Ligand grants Chiva exclusive, worldwide rights to develop and commercialize osteoporosis drug Fablyn lasofoxifene for $4 million

Ligand Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$276.4m on 10/14/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Chiva Pharmaceuticals Inc.

China / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced